CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Clinical trials for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) trials appear
Sign up with your email to follow new studies for CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for transplant patients with Hard-to-Treat complications
Disease control Recruiting nowThis study is testing whether an experimental drug called vimseltinib is safe and effective for adults with moderate to severe chronic graft-versus-host disease (cGVHD) who haven't improved with at least two previous treatments. Participants will take the drug in 28-day cycles fo…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase: PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for transplant patients: testing better first treatment for dangerous complication
Disease control Recruiting nowThis study aims to find the better first treatment for chronic graft-versus-host disease (cGVHD), a serious complication that can occur after a bone marrow transplant. Researchers will compare two drugs—ruxolitinib (already approved for later treatment) and prednisone (current st…
Matched conditions: CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC